This training event will offer lectures and workshops to understand the role for using imaging in drug discovery, drug development and as part of clinical studies. Participants will engage in group debate about the challenges of using imaging in modern drug studies and learn about the routes for resolving those challenges.
This event is subsidised by EMI and we are able to offer this event at a very good rate of £62.
Some delegates are exempt from payment.
PAY: Students- EMI and TMAT; ACFs, CLs pay from bursaries. Industry staff pay through company funding.
Fee Exempt: EMI committee, event speakers and helpers, EMIT students and staff not in receipt of a training bursary, CP SpRs, CCTU staff, NHS Trust staff.
Any queries regarding fees eligibility please contact Liz on firstname.lastname@example.org
|08:30 to 09:00||Registration and Refreshments|
|09:00 to 09:15||Opening Remarks
A summary of the learning objectives and aims of the event
Dr Ferdia Gallagher, Cancer Research UK Clinician Scientist Fellow, University of Cambridge and CRUK Cambridge Research Institute and Dr Joseph Cheriyan, Consultant Physician & Clinical Pharmacologist at Addenbrooke’s Hospital, Associate Lecturer, University of Cambridge, Director of the Cardiovascular Trials Office, Vice Chair of the Cambridge Research Ethics Committee, EMI Training Lead
|09:15 to 09:45||Developing new imaging methods for drugs trials
Dr Phil Murphy, Head, Clinical Imaging , GSK
|09:45 to 10:15||Imaging as part of cardiometabolic drug development
Dr Lars Johansson, CSO, Antaros Medical
|10:15 to 10:45||Imaging as part of musculoskeletal drug studies
Dr Jamie McKay, EMI student, Radiology, Cambridge
|10:45 to 11:00||BREAK|
|11:00 to 11:30||Imaging as part of decision-making tools in drug studies
Dr Neel Patel, Consultant Radionuclide Radiologist, University of Oxford & Experimental Medicine Imaging Physician, GSK
|11:30 to 12:00||Image-based high throughput screening in early drug discovery
Dr Svenja Luense, Senior Research Scientist, Cellular Assay Development and High-Content Analysis (HCA).Astra Zeneca, Sweden
|12:00 to 12:30||Machine learning and deep learning for medical imaging in drug studies
Dr Nicolas Brieu, Senior Research Scientist, Definiens
|12:30 to 13:30||LUNCH
Networking and discussion
|13:30 to 14:00||Imaging in clinical trials
Dr Andy Brown, Global Imaging Lead, Clinical Oncology, Astra Zeneca
|14:00 to 14:30||Imaging in neurological drug studies
Professor Ed Bullmore, Head of Psychiatry, Head of Brain Mapping, University of Cambridge
|14:30 to 15:45||BREAK OUT Workshops
4/5 groups lead by a speaker to discuss 1 of 4/5 case studies – challenges and solutions – 45 minutes
Return to lecture theatre to present findings
30 minutes (5/6minutes per group)
Delegate participation and contribution to the discussion and debate is required in these sessions. Explore challenges and pitfalls in context with a specific case and real-time events.
|15:45 to 16:00||BREAK|
|16:00 to 16:45||Imaging in drug development and discovery: benefits and challenges
Professor John Waterton, Professor of Translational Imaging, University of Manchester
|16:45 to 17:00||Discussion summarising ideas and follow-up steps for each case study
Dr Ferdia Gallagher
|17:00 to 19:00||Drinks reception and hot fork buffet
Over hot food and refreshments, delegates have the opportunity to network with colleagues from industry and academia, making new connections and discussing ideas presented during the day.
Paediatric Drug Development
To understand paediatric drug development in experimental medicine research and as part of clinical studies.
Gain an overview of differing disease epidemiology and regulatory considerations, understanding conditions which occur in paediatric populations & adult populations.
To understand the difficulties in managing a ...